Global Pantoprazole API Market

Pantoprazole API Market Insights

The Pantoprazole API Market will rise at a CAGR assessment of 3.2% during the figure season of 2020-2026. One of the most common proton pump inhibitors in the market is Pantoprazole API, which is used to address diseases of the gastroenterology. The mode of action involves acting upon the amount of acid released in the stomach to avoid further digestive damage. The FDA approved an indication of this drug is the treatment of erosive esophagitis, pathological hypersecretory conditions i.e. Zollinger-Ellison syndrome, and heartburn issues such as GERD for patients undergoing the parallel treatment process. Amongst all the indications, GERD is a highly incident disorder, which is why the market of Pantoprazole API will grow faster during the forecast period. Moreover, the availability of the types of oral drugs as per the patient requirements will help the market to grow.

Pantoprazole API Market: By Type for Drug

The generic and branded versions of the drug Pantoprazole are available in the market.  However, based on the prescription data analysis for Pantoprazole, the generic version of this drug will have more market share than the branded version. Branded tablets are marketed under the name of Protonix.

Pantoprazole API Market: By Type of Dosage

Based on the type of dosage, the market has 20 & 40 mg oral tablets. However, as per the survey conducted by various pharma companies, the 20 mg tablet is more powerful than 40 mg in improving the manifestations of indigestion, corrosive spewing forth, and swelling in patients with GERD. Considering this trend, the study suggests that the 20 mg tablet market segment has a larger share than the 40 mg tablet of Pantoprazole.

Pantoprazole API Market: By Route of Administration

The market can be bifurcated into intravenous and oral admission of medications according to the course of the drug. The oral method is investigated to have the biggest offer than the IV method in the market inferable from the accessibility, cost, and level of gastro-based ailment treatment. Moreover, the Pantoprazole infusion is utilized as a momentary treatment to treat Gastroesophageal reflux infection.

Pantoprazole API Market: By Indication

Based on the application of this drug, the market can segment into Gastroesophageal reflux disease (GERD), Erosive Esophagitis, and Zollinger-Ellison Syndrome. The Pantoprazole API is the first line of treatment for Gastroesophageal reflux disease or GERD, hence making this application segment to be the largest in the market. The patient is administrated by an oral or IV method for treating GERD at inpatient and outpatient facilities.

Pantoprazole API Market: By Region

The geographical analysis segment of the Pantoprazole API Market includes Middle East & Africa, CSA, North America, Asia-Pacific, and Europe. The Asia Pacific will predict an ascent in its market development because of rising cases of gastroenterology related diseases. It will be the fastest-growing segment followed by North America. However, the market value is concerned, the North American region will still be a dominant sector in the pharma industry from 2020 to 2026 period.

Pantoprazole API Market Share and Competitor Analysis

Major companies in the market are Actavis (TEVA), Nora Pharma, GSK, Apotex Corporation, Angita Pharma, Mantra Pharma, Ahn-Gook Pharmal, Auro Pharma, Eurofarma Laboratorios, Abbott, Akeda, Devonian, Zydus Pharmaceuticals, Huarun Shuanghe Pharmaceutical, Northeast Pharmaceutical, Nanjing Yiheng Pharmaceutical, NCPC, Torrent Pharma, Nanjing Changao Pharmaceutical,Nosch Labs Private Limited, Harbin Yuheng Pharmaceutical, Shanghai AIDEFA Pharmaceutical, Sinopharm Group, Wuxi Kaifu Pharmaceutical, Yangzijiang Pharmaceutical, and Chengdu Baiyu Pharmaceutical among.

Please note: This is not an exhaustive list of companies profiled in the report.

In June 2019, a group of researchers from the American Gastroenterological Association studied and published a research article on the safe use of PPI (Pantoprazole API) for patients suffering from a chronic acid-related disease such as GERD.

In March 2016, Aurobindo Pharma received the US FDA approval to fabricate and advertise pantoprazole sodium for infusions, utilized for the treatment of gastroesophageal reflux infection, for the North American region.

Check the Press Release on Global Pantoprazole API Market Report